EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of genome-wide DNA methylation analysis to identify prognostic CpG site markers associated with longer survival time in dogs with multicentric high-grade B-cell lymphoma

Yong Bin Teoh iD, Teita Ishizaki, Yumiko Kagawa, Shoko Yokoyama, Jaroslav Jelinek, Yuki Matsumoto, Hirotaka Tomiyasu, Hajime Tsujimoto iD, Mitsuyoshi Takiguchi iD, Jumpei Yamazaki

Journal of Veterinary Internal Medicine · 2024

DOI: 10.1111/jvim.16931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2024. Verfasst von Yong Bin Teoh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Unit, Veterinary Teaching Hospital, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Dog Diseases, Sulfites. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Anicom Specialty Medical Institute Inc, Tokyo, Japan, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

DNA methylation analysis might identify prognostic CpG sites in CHOP-treated dogs with multicentric high-grade B-cell lymphoma (MHGL) with heterogenous prognosis.

Objective

To identify prognostic CpG sites of MHGL through genome-wide DNA methylation analysis with pyrosequencing validation. Animals Test group: 24 dogs. Validation group: 100 dogs. All client-owned dogs were diagnosed with MHGL and treated with CHOP chemotherapy.

Methods

Cohort study. DNA was extracted from lymph node samples obtained via FNA. Genome-wide DNA methylation analysis using Digital Restriction Enzyme Analysis of Methylation (DREAM) was performed on the test group to identify differentially methylated CpG sites (DMCs). Bisulfite pyrosequencing was used to measure methylation status of candidate DMCs in the validation group. Median survival times (MST) were analyzed using Kaplan-Meier (log-rank) product limit method.

Results

DREAM analyzed 101 576 CpG sites. Hierarchical clustering of 16 262 CpG sites in test group identified group with better prognosis (MST = 55-477 days vs 10-301 days, P = .007). Volcano plot identified 1371 differentially methylated CpG sites (DMCs). DMC near the genes of FAM213A (DMC-F) and PHLPP1 (DMC-P) were selected as candidates. Bisulfite-pyrosequencing performed on validation group showed group with methylation level of DMC-F < 40% had favorable prognosis (MST = 11-1072 days vs 8-1792 days, P = .01), whereas group with the methylation level combination of DMC-F < 40% plus DMC-P < 10% had excellent prognosis (MST = 18-1072 days vs 8-1792 days, P = .009). Conclusion and Clinical Importance Methylation status of prognostic CpG sites delineate canine MGHL cases with longer MST, providing owners with information on expectations of potential improved treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, B-CellDog DiseasesSulfitesHumansDogsAnimalsDNA MethylationPrognosisCohort Studies

Stichwörter der Autor:innen

biomarkerscanine DREAMcanine lymphomaepigenetics

Substanzen

hydrogen sulfiteSulfites

Autor:innen und Institutionen

  • Translational Research Unit, Veterinary Teaching Hospital, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • One Health Research Center, Hokkaido University, Sapporo, Hokkaido, Japan.
  • North Lab, Sapporo, Hokkaido, Japan.
  • Coriell Institute for Medical Research, Camden, New Jersey, USA.
  • Anicom Specialty Medical Institute Inc, Tokyo, Japan.
  • Laboratory of Veterinary Internal Medicine, University of Tokyo, Tokyo, Japan.

ORCID-Profile: Yong Bin Teoh, Hajime Tsujimoto, Mitsuyoshi Takiguchi

Förderung

  • Anicom Specialty Medical Institute Inc, Tokyo, Japan
  • Japan Society for the Promotion of Science

Zitieren

APA

Teoh, Y. B., Ishizaki, T., Kagawa, Y., Yokoyama, S., Jelinek, J., Matsumoto, Y., Tomiyasu, H., Tsujimoto, H., Takiguchi, M., & Yamazaki, J. (2024). Use of genome-wide DNA methylation analysis to identify prognostic CpG site markers associated with longer survival time in dogs with multicentric high-grade B-cell lymphoma. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16931

Vancouver

Teoh YB, Ishizaki T, Kagawa Y, Yokoyama S, Jelinek J, Matsumoto Y, et al. Use of genome-wide DNA methylation analysis to identify prognostic CpG site markers associated with longer survival time in dogs with multicentric high-grade B-cell lymphoma. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.16931

BibTeX
@article{Teoh2024,
  author = {Teoh, Yong Bin and Ishizaki, Teita and Kagawa, Yumiko and Yokoyama, Shoko and Jelinek, Jaroslav and Matsumoto, Yuki and Tomiyasu, Hirotaka and Tsujimoto, Hajime and Takiguchi, Mitsuyoshi and Yamazaki, Jumpei},
  title = {Use of genome-wide DNA methylation analysis to identify prognostic CpG site markers associated with longer survival time in dogs with multicentric high-grade B-cell lymphoma},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  doi = {10.1111/jvim.16931}
}
Kostenlos starten →